Categories
Sun Pharma Advanced Research Company Limited — Updates, 30-04-2026: Press Release
30-04-2026 · 09:11 am
SPARC sold its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million. This strategic sale aims to accelerate pipeline development and strengthen its external innovation strategy, utilizing funds from its Sezaby® approval.
No comments yet. Be the first to comment!
All announcements from Sun Pharma Advanced Research Company Limited